Abstract Background Ovarian cancer is the leading gynecologic cancer diagnosed in North America and because related symptoms are not disease specific, this often leads to late detection, an advanced disease state, and the need for chemotherapy. Ovarian cancer is frequently sensitive to chemotherapy at diagnosis but rapid development of drug resistance leads to disease progression and ultimately death in the majority of patients. Results We have generated paclitaxel resistant ovarian cell lines from their corresponding native cell lines to determine driver mechanisms of drug resistance using gene expression arrays. These paclitaxel re...
[[abstract]]Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to...
Purpose: Most patients with ovarian cancer receive paclitaxel chemotherapy, but less than half respo...
<div><p>Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to pac...
Abstract Background Ovarian cancer is the leading gyn...
BackgroundOvarian cancer is the leading gynecologic cancer diagnosed in North America and because re...
Paclitaxel is a frontline drug for the treatment of epithelial ovarian cancer (EOC). However, follow...
Paclitaxel is a frontline drug for the treatment of epithelial ovarian cancer (EOC). However, follow...
Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian canc...
SummaryCytotoxic drug resistance is a major cause of cancer treatment failure. We report an RNA inte...
Development of drug resistance is the main reason for low chemotherapy effectiveness in treating ova...
<div><p>Paclitaxel is recommended as a first-line chemotherapeutic agent against ovarian cancer, but...
Epithelial ovarian cancer (EOC) is a lethal gynecological cancer, of which paclitaxel resistance is ...
The majority of ovarian tumors eventually recur in a drug resistant form. Using cisplatin sensitive ...
The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carb...
PURPOSE: Amplification of cyclin E1 (CCNE1) is associated with poor outcome in breast, lung, and oth...
[[abstract]]Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to...
Purpose: Most patients with ovarian cancer receive paclitaxel chemotherapy, but less than half respo...
<div><p>Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to pac...
Abstract Background Ovarian cancer is the leading gyn...
BackgroundOvarian cancer is the leading gynecologic cancer diagnosed in North America and because re...
Paclitaxel is a frontline drug for the treatment of epithelial ovarian cancer (EOC). However, follow...
Paclitaxel is a frontline drug for the treatment of epithelial ovarian cancer (EOC). However, follow...
Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian canc...
SummaryCytotoxic drug resistance is a major cause of cancer treatment failure. We report an RNA inte...
Development of drug resistance is the main reason for low chemotherapy effectiveness in treating ova...
<div><p>Paclitaxel is recommended as a first-line chemotherapeutic agent against ovarian cancer, but...
Epithelial ovarian cancer (EOC) is a lethal gynecological cancer, of which paclitaxel resistance is ...
The majority of ovarian tumors eventually recur in a drug resistant form. Using cisplatin sensitive ...
The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carb...
PURPOSE: Amplification of cyclin E1 (CCNE1) is associated with poor outcome in breast, lung, and oth...
[[abstract]]Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to...
Purpose: Most patients with ovarian cancer receive paclitaxel chemotherapy, but less than half respo...
<div><p>Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to pac...